---
title: "Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296266412.md"
description: "On August 14, 2026, Cytokinetics, Incorporated (Nasdaq: CYTK) based in South San Francisco, granted stock options for 27,565 shares of common stock and 18,273 restricted stock units (RSUs) to 12 new employees who started in July and August 2026. The RSUs will be converted to common stock upon vesting. This action was taken as a significant incentive for their employment, totaling 45,838 equity units granted."
datetime: "2026-08-18T20:01:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296266412.md)
  - [en](https://longbridge.com/en/news/296266412.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296266412.md)
generator: "portal-rs"
---

# Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

On August 14, 2026, Cytokinetics, Incorporated (Nasdaq: CYTK) based in South San Francisco, granted stock options for 27,565 shares of common stock and 18,273 restricted stock units (RSUs) to 12 new employees who started in July and August 2026. The RSUs will be converted to common stock upon vesting. This action was taken as a significant incentive for their employment, totaling 45,838 equity units granted.

### Related Stocks

- [CYTK.US](https://longbridge.com/en/quote/CYTK.US.md)

## Related News & Research

- [Cytokinetics EVP R&D Malik Fady Ibraham disposes of 3,500 common shares for $264,110](https://longbridge.com/en/news/298363335.md)
- [RBC Capital Keeps Their Buy Rating on Cytokinetics (CYTK)](https://longbridge.com/en/news/297724700.md)
- [Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells 7,500 Shares](https://longbridge.com/en/news/297562601.md)
- [Cytokinetics CEO Robert I. Blum disposes of $526,800 in common shares](https://longbridge.com/en/news/297561222.md)
- [Goldman Sachs Reaffirms Their Buy Rating on Cytokinetics (CYTK)](https://longbridge.com/en/news/297484061.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**